CONTEXT: Fasting is associated with suppressed insulin and augmented GH secretion. The involvement of each mechanism in the regulation of fuel mobilization during fasting is unknown. OBJECTIVE: To ascertain the role of GH in the regulation of the rates of lipolysis, proteolysis, and hepatic glucose production (HGP) during the physiological daily feed/fast cycle and after 2 d of complete fasting, we used a model of selective GH suppression by the administration of GHRH receptor antagonist (GHRH-A). DESIGN AND SETTING: We conducted an open label in-patient study in the General Clinical Research Center at the University of Michigan. PARTICIPANTS: Six healthy, nonobese volunteers participated. MAIN OUTCOME MEASURES: We assessed 24-h plasma GH concentration and rates of lipolysis, proteolysis, and HGP using stable isotope techniques after an overnight fast and after 2 d of fasting. RESULTS: GHRH-A suppressed plasma GH by about 65% during the fed state (P = 0.015) but did not alter the rates of lipolysis, proteolysis, or HGP. Fasting for 2 d suppressed plasma insulin concentration by about 80% and elevated plasma GH about 4-fold (both P < 0.01). This was accompanied by a doubling in the rate of lipolysis, an approximately 40% increase in proteolysis, and an approximately 30% decline in HGP (all P < 0.05). Preventing the fasting-induced increase in GH with GHRH-A largely abolished the increase in the rate of lipolysis. GHRH-A also augmented the fasting-induced reduction in HGP but did not alter proteolysis. CONCLUSIONS: Endogenous GH plays a very limited metabolic role during the daily feed/fast cycle but is essential for the increased lipolytic rate found with more prolonged fasting.
CONTEXT: Fasting is associated with suppressed insulin and augmented GH secretion. The involvement of each mechanism in the regulation of fuel mobilization during fasting is unknown. OBJECTIVE: To ascertain the role of GH in the regulation of the rates of lipolysis, proteolysis, and hepatic glucose production (HGP) during the physiological daily feed/fast cycle and after 2 d of complete fasting, we used a model of selective GH suppression by the administration of GHRH receptor antagonist (GHRH-A). DESIGN AND SETTING: We conducted an open label in-patient study in the General Clinical Research Center at the University of Michigan. PARTICIPANTS: Six healthy, nonobese volunteers participated. MAIN OUTCOME MEASURES: We assessed 24-h plasma GH concentration and rates of lipolysis, proteolysis, and HGP using stable isotope techniques after an overnight fast and after 2 d of fasting. RESULTS:GHRH-A suppressed plasma GH by about 65% during the fed state (P = 0.015) but did not alter the rates of lipolysis, proteolysis, or HGP. Fasting for 2 d suppressed plasma insulin concentration by about 80% and elevated plasma GH about 4-fold (both P < 0.01). This was accompanied by a doubling in the rate of lipolysis, an approximately 40% increase in proteolysis, and an approximately 30% decline in HGP (all P < 0.05). Preventing the fasting-induced increase in GH with GHRH-A largely abolished the increase in the rate of lipolysis. GHRH-A also augmented the fasting-induced reduction in HGP but did not alter proteolysis. CONCLUSIONS: Endogenous GH plays a very limited metabolic role during the daily feed/fast cycle but is essential for the increased lipolytic rate found with more prolonged fasting.
Authors: Matthew P Harber; Simon Schenk; Ariel L Barkan; Jeffrey F Horowitz Journal: Am J Physiol Endocrinol Metab Date: 2005-03-29 Impact factor: 4.310
Authors: Isadora C Furigo; Gabriel O de Souza; Pryscila D S Teixeira; Dioze Guadagnini; Renata Frazão; Edward O List; John J Kopchick; Patricia O Prada; Jose Donato Journal: FASEB J Date: 2019-07-31 Impact factor: 5.191
Authors: Alécia A Oliveira-Santos; Roberto Salvatori; Elenilde Gomes-Santos; João A M Santana; Ângela C G B Leal; Rita A A Barbosa; Carla R P Oliveira; Anita H O Souza; Eugênia H O Valença; Manuel H Aguiar-Oliveira Journal: Endocrine Date: 2015-06-23 Impact factor: 3.633
Authors: Brandon C Sos; Charles Harris; Sarah M Nordstrom; Jennifer L Tran; Mercedesz Balázs; Patrick Caplazi; Maria Febbraio; Milana A B Applegate; Kay-Uwe Wagner; Ethan J Weiss Journal: J Clin Invest Date: 2011-04 Impact factor: 14.808
Authors: Daniel W D West; Ann Lee-Barthel; Todd McIntyre; Baubak Shamim; Cassandra A Lee; Keith Baar Journal: J Physiol Date: 2015-09-14 Impact factor: 5.182
Authors: Louise Moller; Helene Norrelund; Niels Jessen; Allan Flyvbjerg; Steen B Pedersen; Bruce D Gaylinn; Jianhua Liu; Michael O Thorner; Niels Moller; Jens Otto Lunde Jorgensen Journal: J Clin Endocrinol Metab Date: 2009-10-09 Impact factor: 5.958